U.S. Markets closed

Lineage Cell Therapeutics, Inc. (LCTX)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.5600-0.0500 (-1.92%)
At close: 4:00PM EDT
2.5700 +0.02 (0.98%)
After hours: 04:09PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.6100
Open2.5300
Bid2.5700 x 1100
Ask2.5800 x 900
Day's Range2.5400 - 2.6500
52 Week Range0.8200 - 3.1300
Volume478,398
Avg. Volume1,363,101
Market Cap413.793M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.3730
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
  • OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
    Business Wire

    OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy

    CARLSBAD, Calif., July 20, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells, administered one time to the subretinal space, for the treat

  • OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
    Business Wire

    OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

    CARLSBAD, Calif., July 13, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be featured in a podium presentation at the

  • Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
    Business Wire

    Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes

    CARLSBAD, Calif., June 28, 2021--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has been added to both the broad-market Russell 3000® Index as well as the Russell Microcap® Index. The 2021 Russell indexes annual reconstitution will be effective after the U.S. market opens today.